Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17364397 | 0.84 | ADORA3 (0.38) | ADORA3ADORA2B | |
| SCHEMBL1945913 | 0.82 | PIK3CA (0.41) | PIK3CACHRM2CHRM4CHRM1ADORA3 | |
| SCHEMBL1946473 | 0.81 | PIK3CA (0.33) | PIK3CACHRM2CHRM4CHRM1CHRM5 | |
| SCHEMBL1944180 | 0.80 | TSHR (0.48) | CHRM2CHRM4CHRM1ADORA3ADORA2B | |
| SCHEMBL1943200 | 0.78 | ADORA3 (0.35) | ADORA3ADORA2BJAK2JAK3 | |
| SCHEMBL1945510 | 0.75 | PIK3CA (0.36) | PIK3CAADORA3ADORA2B | |
| SCHEMBL1944256 | 0.71 | PIK3CA (0.36) | PIK3CACHRM2CHRM4CHRM1CHRM5 | |
| SCHEMBL1944363 | 0.70 | ALDH1A1 (0.44) | PIK3CACHRM2CHRM4CHRM1CHRM5 | |
| SCHEMBL1944566 | 0.70 | KMT2A (0.44) | PIK3CACHRM2CHRM4CHRM1CHRM5 | |
| SCHEMBL1546118 | 0.65 | ALDH1A1 (0.49) | ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7795269-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7741331-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009157938-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER | CV THERAPEUTICS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009088518-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | CV THERAPEUTICS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-7105665-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1622908-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 961/4885CHRM2 256/4885CHRM4 1176/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1517/4885CHRM2 264/4885CHRM4 573/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1517/4885CHRM2 264/4885CHRM4 573/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PIK3CA 1497/4885CHRM2 227/4885CHRM4 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.